☆Foresite Capital Management IV, LLC
Quality Q
0.804
AUM ($M)
290
Positions
6
Turnover
0.13
Top-10 wt
100%
Herfindahl
0.384
History (qtrs)
6
Excess Return
+42.9%
AI Eval Run AI Eval
Holdings · 9 positions · portfolio value $290M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆PHVS funds › | Pharvaris N.V. | HOLD | — | 57.0% | +0.0% | 165.2 | 4,778,581 | +0 | 5 | — |
| ☆CYTK funds › | CYTOKINETICS INC | ADD | Common Stock | 21.0% | +7.0% | 60.9 | 714,695 | +211,400 | 4 | — |
| ☆EIKN funds › | Eikon Therapeutics, Inc. | HOLD | Common Stock | 8.7% | +0.1% | 25.4 | 1,943,682 | +0 | 2 | -83.0% |
| ☆RLAY funds › | Relay Therapeutics, Inc. | ADD | — | 8.1% | +3.9% | 23.4 | 1,250,000 | +250,000 | 5 | — |
| ☆XENE funds › | Xenon Pharmaceuticals Inc. | HOLD | — | 3.3% | -0.6% | 9.7 | 160,000 | +0 | 5 | — |
| ☆CRNX funds › | Crinetics Pharmaceuticals, Inc. | NEW | — | 1.9% | +1.9% | 5.6 | 150,000 | +150,000 | 1 | — |
| ☆MAZE funds › | Maze Therapeutics, Inc. | EXIT | — | 0.0% | -2.0% | 0.0 | 0 | -156,901 | 0 | — |
| ☆LYEL funds › | Lyell Immunopharma, Inc. | EXIT | — | 0.0% | -6.8% | 0.0 | 0 | -800,399 | 0 | — |
| ☆ALEC funds › | Alector, Inc. | EXIT | Common Stock | 0.0% | -3.5% | 0.0 | 0 | -3,887,200 | 0 | +168.7% |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 290 | 6 | 0.13 | 100% | 0.384 | 0.803 | — | in |
| 2026Q1 | 237 | 8 | 0.12 | 100% | 0.361 | 0.796 | — | in |
| 2025Q4 | 230 | 7 | 0.09 | 100% | 0.373 | 0.805 | — | in |
| 2025Q3 | 183 | 6 | 0.18 | 100% | 0.458 | 0.633 | — | in |
| 2025Q2 | 124 | 6 | 0.11 | 100% | 0.444 | 0.744 | — | entered |
| 2025Q1 | 111 | 5 | 0.00 | 100% | 0.443 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status